The purpose of the public workshop — organized by the Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA) — is to foster development of individualized therapeutic products for the treatment of one individual or a very small number of patients, based on engineering a product aimed at the specific molecular mechanism underlying a patient’s (or small group of patients’) illness.
SCB will be attending.